JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Maximum Tolerated Dose Estimation Applied Biased Coin Design in a Phase I Clinical Trial
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Maximum Tolerated Dose Estimation Applied Biased Coin Design in a Phase I Clinical Trial
Kim, Yu Rim; Kim, Dongjae;
  PDF(new window)
 Abstract
Phase I trials determine the maximum tolerated dose(MTD) and the recommended dose(RD) for subsequent Phase II trials. In this paper, a MTD estimation method applied to a biased coin design is proposed for Phase I Clinical Trials. The suggested MTD estimation method is compared to the SM3 method and the NM method (Lee and Kim, 2012) using a Monte Carlo simulation study.
 Keywords
Phase I clinical trial;maximum tolerated dose;recommended dose;biased coin design;
 Language
Korean
 Cited by
 References
1.
Ahn, C. (1998). An evaluation of phase I cancer clinical trial designs, Statistics in Medicine, 17, 1537- 1549. crossref(new window)

2.
Antognini, A. B. and Giovagnoli, A. (2004). A new "biased coin design" for the sequential allocation of two treatments, Italian Statistical Society.

3.
Chevret, S. (1993). The continual reassessment method in cancer phase I clinical trials: A simulation study, Statistics in Medicine, 12, 1093-1108. crossref(new window)

4.
Dixon, W. J. and Mood, A. M. (1948). A method for obtaining and analyzing sensitivity data, Journal of the American Statistical Association, 43, 109-126. crossref(new window)

5.
Goodman, S. N., Zhurak, M. L. and Piantadosi, S. (1995). Some practical improvements in the continual reassessment method for Phase I studies, Statistics in Medicine, 14, 1149-1161. crossref(new window)

6.
Kang, S. H. (2002). Investigation on the modified continual reassessment method in phase I clinical trial, Journal of Applied Statistics, 15, 323-336. crossref(new window)

7.
Korn, E. L., Midthune, D., Chen, T. T., Rubinstein, L. V., Christian, M. C. and Simon, R. M. (1994). A comparison of two phase I trial designs, Statistics in Medicine, 13, 1799-1806. crossref(new window)

8.
Lee, N. M. and Kim, D. (2012). Two-stage maximum tolerated dose estimation by stopping rule in a phase I clinical trial, Communications of the Korean Statistical Society.

9.
O'Quigley, J. and Chevret, S. (1991). Method for dose finding studies in cancer clinical trials: A review and results of a Monte Carlo study, Statistics in Medicine, 10, 1647-1664. crossref(new window)

10.
O'Quigley, J., Pepe, M. and Fisher, M. (1990). Continual reassessment method: A practical design for phase I clinical trials in cancer, Biometrics, 46, 33-48. crossref(new window)

11.
O'Quigley, J. and Shen, L. Z. (1996). Continual reassessment method: A likelihood approach, Biometrics, 52, 163-174.

12.
Park, I. H. (1999). The estimation of maximal tolerated dose in sequential phase I clinical trials, Department of Biostatistics, The Catholic University of Korea, Biostatistics Master's Thesis.

13.
Storer, B. E. (1989). Design and analysis of phase I clinical trials, Biometrics, 45, 925-937. crossref(new window)